Letter to the editor
Deselecting Melanoma Patients for Sentinel Lymph Node Biopsy During COVID-19: Clinical Utility of Tumor Molecular Profiling

https://doi.org/10.1016/j.mayocpiqo.2020.05.009Get rights and content
Under a Creative Commons license
open access

Cited by (0)

Potential Competing Interests: Dr Meves reports a financial interest in a molecular test (CP-GEP) being developed by SkylineDx in the area of melanoma. Mayo Clinic has reviewed this relationship and taken appropriate steps to protect the scientific integrity of the research. Dr Eggermont has an equity stake in SkylineDx.

Grant Support: Supported by the National Cancer Institute: grant CA215105.